Top Performing Large-Cap Stocks Last Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 08 2026
0mins
Should l Buy LITE?
Source: Benzinga
- Lumentum Earnings Beat: Lumentum Holdings Inc. surged 36.02% this week after reporting second-quarter results that exceeded expectations and providing third-quarter guidance above analyst estimates, thereby boosting investor confidence and significantly driving up the stock price.
- Transportation Stocks Rally: Saia, Inc. jumped 23.07% this week, benefiting from declining oil prices, which led to a strong performance across the transportation sector, indicating optimistic market expectations for transportation demand that could enhance future earnings.
- Westlake Stock Increase: Westlake Corporation saw a 19.27% rise in its stock price this week, reflecting positive market sentiment regarding its business outlook, particularly in the context of declining raw material costs that may improve profitability.
- Market Recovery: The strong performance of these stocks indicates a growing investor confidence in economic recovery, especially amid falling oil prices, which could further drive growth in related industries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LITE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LITE
Wall Street analysts forecast LITE stock price to fall
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 558.440
Low
147.00
Averages
303.36
High
470.00
Current: 558.440
Low
147.00
Averages
303.36
High
470.00
About LITE
Lumentum Holdings Inc. is a designer and manufacturer of optical and photonic products enabling optical networking and laser applications worldwide. Its segments include Cloud & Networking and Industrial Tech. The Cloud & Networking segment products include a comprehensive portfolio of optical and photonic components, modules, and subsystems supplied to cloud and communications network operators and network equipment manufacturers building cloud data center infrastructure, including products for artificial intelligence and machine learning (AI/ML) and data center interconnect (DCI) applications, and communications service provider networks, including products for access (local), metro (intracity), long-haul (city-to-city and worldwide), and submarine (undersea) network infrastructure. The Industrial Tech segment products include solid-state lasers, kilowatt-class fiber lasers, diode lasers, ultrafast lasers, and gas lasers, which address applications in numerous end-markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nvidia Invests in Optical Firms Joining S&P 500
- Strategic Investment: Nvidia announced a $2 billion investment in both Lumentum and Coherent, aiming to enhance energy efficiency and resilience in AI factories through optical interconnect technology, thereby strengthening its competitive edge in data center infrastructure.
- S&P 500 Inclusion: Lumentum and Coherent's admission to the S&P 500 index marks a significant boost in their market credibility, which is expected to attract index fund purchases and drive their stock prices higher in the short term.
- Stock Price Surge: Over the past year, Lumentum and Coherent's stock prices have skyrocketed by 279% and 932%, respectively, indicating strong market confidence in their growth potential, with current P/E ratios at 34 and 45 times expected earnings.
- Technological Significance: Nvidia highlighted the critical role of optical interconnect technology in the ongoing scaling of AI networks, and this investment will secure essential data center infrastructure components to support future AI advancements.
See More
Nvidia Invests in Optics Firms Lumentum and Coherent, Both Join S&P 500
- Strategic Investment: Nvidia announced a $2 billion investment in both Lumentum and Coherent as part of a multiyear strategic partnership, which is expected to enhance its technological integration and market competitiveness in the artificial intelligence sector.
- S&P 500 Inclusion: The admission of Lumentum and Coherent into the S&P 500 index represents a significant milestone that will enhance their credibility among investors and could further boost their stock prices through passive purchases by index funds.
- Stock Price Surge: Over the past year, Coherent and Lumentum have seen their stock prices increase by 279% and 932%, respectively, indicating strong market recognition of the critical role of optical components in data centers and reflecting investor confidence in their future growth potential.
- Technological Significance: Nvidia emphasized that optical interconnect technology and package integration are crucial for the continued scaling of AI factories, and this investment not only secures essential data center infrastructure components but may also enhance overall energy efficiency and network resilience.
See More
U.S. Markets Increased on Monday, with Lumentum Holdings Leading the Gains
- Stock Market Performance: U.S. stock indexes experienced an upward trend on Monday.
- Index Gains: The S&P 500 rose by 1.38%, the Dow Jones increased by 0.83%, and the Nasdaq added 0.50%.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Middle East Tensions Impact Global Markets
- Market Decline: Wall Street opened the week in negative territory, with the S&P 500 falling 0.5% to around 6,700 points, reflecting investor concerns over Middle East tensions that could lead to increased market volatility.
- Rising Oil Prices: WTI crude oil surged about 6% to $97 per barrel, while Brent climbed to $98.31, although both benchmarks trimmed larger overnight gains in futures trading, indicating heightened worries over potential supply disruptions.
- Policy Response Expectations: U.S. President Trump is expected to announce measures to ease surging oil prices, including a coordinated release of strategic petroleum reserves by G7 countries, highlighting the seriousness with which major economies are addressing the risk of prolonged supply disruptions.
- Escalating Geopolitical Tensions: NATO intercepted an Iranian ballistic missile heading toward Turkey on Monday, signaling rising concerns that the regional conflict could expand, further increasing market uncertainty.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Nvidia Invests in Optical Firms Joining S&P 500
- Strategic Investment: Nvidia announced a $2 billion investment in both Lumentum and Coherent, aiming to enhance energy efficiency and resilience in AI factories through optical interconnect technology, thereby strengthening its competitive edge in data center infrastructure.
- S&P 500 Inclusion: Lumentum and Coherent's admission to the S&P 500 index marks a significant boost in their market credibility, which is expected to attract index fund purchases and drive their stock prices higher in the short term.
- Stock Price Surge: Over the past year, Lumentum and Coherent's stock prices have skyrocketed by 279% and 932%, respectively, indicating strong market confidence in their growth potential, with current P/E ratios at 34 and 45 times expected earnings.
- Technological Significance: Nvidia highlighted the critical role of optical interconnect technology in the ongoing scaling of AI networks, and this investment will secure essential data center infrastructure components to support future AI advancements.
See More
Nvidia Invests in Optics Firms Lumentum and Coherent, Both Join S&P 500
- Strategic Investment: Nvidia announced a $2 billion investment in both Lumentum and Coherent as part of a multiyear strategic partnership, which is expected to enhance its technological integration and market competitiveness in the artificial intelligence sector.
- S&P 500 Inclusion: The admission of Lumentum and Coherent into the S&P 500 index represents a significant milestone that will enhance their credibility among investors and could further boost their stock prices through passive purchases by index funds.
- Stock Price Surge: Over the past year, Coherent and Lumentum have seen their stock prices increase by 279% and 932%, respectively, indicating strong market recognition of the critical role of optical components in data centers and reflecting investor confidence in their future growth potential.
- Technological Significance: Nvidia emphasized that optical interconnect technology and package integration are crucial for the continued scaling of AI factories, and this investment not only secures essential data center infrastructure components but may also enhance overall energy efficiency and network resilience.
See More
U.S. Markets Increased on Monday, with Lumentum Holdings Leading the Gains
- Stock Market Performance: U.S. stock indexes experienced an upward trend on Monday.
- Index Gains: The S&P 500 rose by 1.38%, the Dow Jones increased by 0.83%, and the Nasdaq added 0.50%.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Middle East Tensions Impact Global Markets
- Market Decline: Wall Street opened the week in negative territory, with the S&P 500 falling 0.5% to around 6,700 points, reflecting investor concerns over Middle East tensions that could lead to increased market volatility.
- Rising Oil Prices: WTI crude oil surged about 6% to $97 per barrel, while Brent climbed to $98.31, although both benchmarks trimmed larger overnight gains in futures trading, indicating heightened worries over potential supply disruptions.
- Policy Response Expectations: U.S. President Trump is expected to announce measures to ease surging oil prices, including a coordinated release of strategic petroleum reserves by G7 countries, highlighting the seriousness with which major economies are addressing the risk of prolonged supply disruptions.
- Escalating Geopolitical Tensions: NATO intercepted an Iranian ballistic missile heading toward Turkey on Monday, signaling rising concerns that the regional conflict could expand, further increasing market uncertainty.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
